Antibe Therapeutics Looking for More Licensing Deals
Antibe Therapeutics is trying to change the game of non-steroidal anti-inflammatory drugs (NSAID)—the “largest category of drugs globally,” CEO Dan...
Aerpio Announces Initiation of Dosing in a Phase 1a, Multiple-Ascending Dose Study of AKB-4924
Aerpio Pharmaceuticals (OTCQB:ARPO), today announced the initiation of dosing in a Phase 1a, multiple-ascending dose study of the Company’s hypoxia-inducible...
Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine
Pfizer (NYSE:PFE) today announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate...
Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and...
Evotec and Celgene Enter into Strategic Oncology Partnership
Evotec (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that Evotec and Celgene Corporation have entered into a long-term...
XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis
XBiotech Inc. (NASDAQ:XBIT) announced today that the first patient has been enrolled in its Phase 2 open label, dose escalation...
BioCorRx Announces Grant Submission to the National Institutes of Health for BICX102
BioCorRx (OTCQB: BICX) a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced it...
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-2029, a CD71-Directed Probody Therapeutic
CytomX Therapeutics (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™...
International Stem Cell Corporation Announces Operating Results for the Quarter Ended March 31, 2018
International Stem Cell (OTCQB:ISCO) a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided...
Aileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at Dana-Farber Cancer Institute
Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced the...
